Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ainos, Inc. (NASDAQ: AIMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Texas corporation with shares listed on the Nasdaq Stock Market, Ainos submits periodic reports, proxy statements, and current reports that document its financial condition, governance decisions, and material agreements.
For investors tracking Ainos’ transition into an AI-powered digital olfaction and SmellTech company, Form 10-K annual reports and Form 10-Q quarterly reports are key sources for detailed discussions of the AI Nose platform, Smell Language Model (SLM), VELDONA oral interferon program, research and development spending, and risk factors. Form 8-K current reports capture material events such as financial result announcements, entry into or amendments of product development agreements, and other significant corporate actions.
Ainos’ DEF 14A proxy statements provide insight into board elections, auditor ratification, stock award proposals, and shareholder voting outcomes, reflecting how the company structures its governance and equity incentives. Filings also identify Ainos’ state of incorporation, trading symbols (AIMD for common stock and AIMDW for warrants), and other corporate details.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly understand changes in capital structure, major contracts, or strategic direction without reading every page. Real-time updates from EDGAR ensure that new Ainos filings, including Forms 4 reporting insider transactions when available, appear promptly, while AI-generated overviews of 10-Ks and 10-Qs make complex disclosures more accessible to both experienced and newer investors.
Ainos, Inc. (AIMD) reported an insider equity transaction by a director. On 11/25/2025, the reporting person received 50,000 shares of common stock as special stock awards at a reported price of $2.10 per share, increasing their directly held stake to 90,880 shares after the transaction. These 50,000 shares were granted and vested as part of special stock awards that had been approved by Ainos stockholders on 11/7/2025. The filing also shows related movements in restricted stock units and their conversion into common stock.
Ainos, Inc. (AIMD) reported that its Chief Financial Officer received a special stock award. On November 25, 2025, the CFO acquired 20,000 shares of common stock at a price of $2.10 per share, following the vesting of a restricted stock unit grant reported in the derivative table. After this transaction, the CFO beneficially owns 75,275 shares of Ainos common stock directly. The company’s stockholders had previously approved these special stock awards on November 7, 2025.
Ainos, Inc. (AIMD) reported an insider equity transaction by a director. On November 25, 2025, the director received 50,000 shares of common stock as special stock awards, which were granted and vested on that date. The awards were previously approved by Ainos stockholders on November 7, 2025.
The filing shows the 50,000 shares were acquired at a price of $2.10 per share, increasing the director’s directly held stake to 90,880 shares of Ainos common stock following the transaction. The Form 4 also reflects related movements in restricted stock units (RSUs) that converted into the same number of common shares.
Ainos, Inc. (AIMD)November 25, 2025, the reporting person, serving as a director, acquired 80,000 shares of common stock at $2.10 per share, following the vesting of 80,000 restricted stock units (RSUs) granted as special stock awards. After this transaction, the director beneficially owned 356,999 shares of Ainos common stock in direct ownership. The filing notes that these special stock awards were approved by Ainos stockholders on November 7, 2025.
Ainos, Inc. (AIMD) filed its Q3 2025 10‑Q, reporting continued operating losses with limited cash. Nine‑month revenue was $113,037, up from $20,729, driven mainly by VOC sensing co‑development and modest VELDONA Pet sales. Net loss was $10,302,714, and operating loss reached $9,692,751. Cash and cash equivalents were $1,128,217 at September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern.
To support liquidity, Ainos used its at‑the‑market program with H.C. Wainwright, selling 674,867 shares for $1,852,895 in net proceeds through September 30 and an additional 18,837 shares for $68,151 from October 1 to November 13. Shares outstanding were 4,793,797 as of September 30 and 4,812,634 as of November 13, 2025, following a 1‑for‑5 reverse split effective June 30. R&D expenses were $5,626,514 and SG&A $4,159,627 for the first nine months, reflecting ongoing investment in AI Nose, POCT, and VELDONA development while the business advances pilot deployments and partnerships.
Ainos, Inc. (AIMD) filed an 8-K detailing shareholder voting results and the furnishing of a press release with results for the quarter ended September 30, 2025.
At the November 7 Annual Meeting, a quorum was present with 3,226,793 votes, representing approximately 67.63% of outstanding votes. Seven directors were elected with vote support near or above 98%. Shareholders approved the ratification of YCM CPA INC. as independent auditor for the fiscal year ending December 31, 2025.
Shareholders also approved the reservation of up to 950,000 shares of common stock as special stock awards not issued under the 2023 Stock Incentive Plan. As of the September 17 record date, 4,771,184 common shares were outstanding and entitled to vote. The company furnished, but did not file, a press release announcing quarterly results as Exhibit 99.1.
Ainos, Inc. entered a Fourth Addendum to its Product Development Agreement with Taiwan Carbon Nano Technology Corporation (TCNT). The amendment sets a fee for the exclusive use of patents of $50,000 per month plus 5% sales tax for a two-year period starting October 16, 2025, replacing the prior one-year period starting October 16, 2024.
TCNT controls the company through its majority interest in Ainos KY and direct ownership, with Ainos KY holding majority voting power via voting agreements. The parties may negotiate payment terms and subsequent licensing methods after the two-year period. An English translation of the Fourth Addendum is filed as Exhibit 10.1.
Taiwan Carbon Nano Technology Corporation (TCNT) reports it directly holds 1,037,206 shares of Ainos, Inc. common stock, representing 21.79% of the outstanding shares after the issuer's one-for-five reverse stock split. TCNT acquired a larger position when the issuer issued 5,500,000 shares under a license agreement in exchange for patent rights and subsequently adjusted for the reverse split.
TCNT sold 62,794 shares between the end of June and early October and states those sales were for general operating purposes. TCNT is subject to a voting agreement that requires it to vote its shares as directed by Ainos KY while Ainos KY holds at least 10% of the issuer's shares. No litigation or other arrangements are disclosed.
Ainos Inc. amended its Schedule 13D to report ownership and recent transactions involving the issuer's common stock. After a
The filing states the direct holdings of
Form 4 disclosure: Taiwan Carbon Nano Technology Corporation, reported by Chun-Hsien Tsai as reporting person, recorded an insider sale in Ainos, Inc. (AIMD). On